Clinical Trial Update: Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of carboplatin plus bevacizumab for triple-negative metastatic breast cancer; the study was terminated and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-04-15